Loading the section
Closing prices for 09 October 2026
Next earnings report: 04 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Glaukos Corporation trades on NYSE under the ticker GKOS. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks GKOS has traded between 73.16 $ and 191.62 $. As of 09 October 2026 the price stood 78.11 % of the way from the 52-week low to the high.
Over one year GKOS shares rose 89.17 %; over six months they rose 42.35 %. Volatility over 90 days is 40.30 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 16.9, above the sector median of 3.9. Price to book is 13.9, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 160.06 | 166.97 | 159.89 | 165.69 | 1M |
| 08 October 2026 | 170.67 | 170.86 | 146.39 | 161.29 | 3M |
| 07 October 2026 | 161.00 | 174.48 | 159.59 | 172.18 | 1M |
| 06 October 2026 | 163.84 | 164.00 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Glaukos makes micro-implants that lower pressure inside the eye in glaucoma.
Glaucoma develops slowly and irreversibly: sight is lost gradually, while drops must be instilled daily for years and patients do not do it. A tiny stent placed during cataract surgery drains fluid continuously and removes the dependence on patient discipline.
The procedure is performed alongside an operation already scheduled, which removes the main barrier — persuading a patient to accept a separate intervention. The second line is a treatment that strengthens a thinning cornea. Risks: insurer reimbursement decisions, competition from ophthalmic device makers and trial outcomes. The company pays no dividend.
Address:1 GLAUKOS WAY, ALISO VIEJO, CA, 92656, US
Glaukos Corporation reported revenue of 551M $ and a net loss of 189M $ over the last four quarters. Net margin is −34.34 %. Revenue changed by +36.30 % year over year. Earnings per share are −3.30 $. Market capitalisation is 9.3B $.
GKOS has a return on equity of −28.22 %, above the sector median of −41.68 %. Return on assets is −21.19 %, above the sector median of −32.11 %. Operating margin is −36.05 %, below the sector median of −26.84 %.
| 325M |
| DXCMDexCom, Inc. | 84.15 | −0.31 % | 324M |
| MDLNMedline Inc. | 36.26 | +1.45 % | 297M |
| RMDResMed Inc. | 230.43 | +1.63 % | 276M |
| PODDInsulet Corporation | 135.28 | +0.60 % | 244M |
| 160.30 |
| 161.59 |
| 664,400 |
| 05 October 2026 | 164.44 | 165.99 | 163.17 | 164.01 | 837,800 |
| 02 October 2026 | 167.57 | 168.08 | 163.01 | 163.75 | 742,800 |
| 01 October 2026 | 164.00 | 168.73 | 162.08 | 163.17 | 808,400 |
| 30 September 2026 | 158.31 | 165.65 | 157.29 | 164.19 | 947,000 |
| 29 September 2026 | 153.56 | 159.06 | 152.39 | 158.55 | 638,200 |
| 28 September 2026 | 153.11 | 160.98 | 151.71 | 158.56 | 1M |
| 25 September 2026 | 154.50 | 155.60 | 151.01 | 154.43 | 826,200 |
| 24 September 2026 | 153.70 | 156.65 | 152.75 | 154.88 | 838,400 |
| 23 September 2026 | 159.86 | 162.04 | 153.31 | 153.49 | 1M |
| 22 September 2026 | 165.36 | 165.36 | 159.00 | 159.86 | 1M |
| 21 September 2026 | 166.27 | 166.74 | 160.23 | 161.53 | 806,500 |
| 18 September 2026 | 160.60 | 163.85 | 159.01 | 163.81 | 1M |
| 17 September 2026 | 164.13 | 166.36 | 160.68 | 161.42 | 646,800 |
| 16 September 2026 | 172.01 | 173.55 | 162.12 | 163.47 | 691,000 |
| 15 September 2026 | 169.75 | 172.76 | 167.97 | 171.68 | 621,700 |
| 14 September 2026 | 168.51 | 171.36 | 165.43 | 171.09 | 906,300 |